CellCentric has reeled in a $220 million Series D to help it address multiple myeloma patients who have exhausted all other treatment options.
CellCentric has reeled in a massive fund to help it address multiple myeloma patients who have exhausted all other treatment options.
The 22-year-old transatlantic biotech …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
CellCentric raises $220M for a ‘transformative’ multiple myeloma medicine
Biotech raises $42 million to run Huntington’s disease trial
Novo Nordisk's less-bad news on its Wegovy pill boosts earnings and share price
Musely secures $360M from General Catalyst without giving up equity | TechCrunch
FDA revisits a rare cancer treatment it rejected a few months ago
Angelini to buy Catalyst in $4B play for rare neuro drugs
Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B
FDA to reevaluate spurned cell therapy; Under-the-skin Leqembi review extended
